CN113993883A - 一种多肽及其应用 - Google Patents
一种多肽及其应用 Download PDFInfo
- Publication number
- CN113993883A CN113993883A CN202080042030.2A CN202080042030A CN113993883A CN 113993883 A CN113993883 A CN 113993883A CN 202080042030 A CN202080042030 A CN 202080042030A CN 113993883 A CN113993883 A CN 113993883A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- seq
- modification
- group
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 76
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 71
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 70
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 claims abstract description 18
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 230000004048 modification Effects 0.000 claims description 32
- 238000012986 modification Methods 0.000 claims description 32
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 9
- 239000008117 stearic acid Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 238000011191 terminal modification Methods 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 238000005576 amination reaction Methods 0.000 claims description 2
- 230000006287 biotinylation Effects 0.000 claims description 2
- 238000007413 biotinylation Methods 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000001215 fluorescent labelling Methods 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 238000002715 modification method Methods 0.000 claims description 2
- 230000007498 myristoylation Effects 0.000 claims description 2
- 230000026792 palmitoylation Effects 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000013823 prenylation Effects 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 235000009200 high fat diet Nutrition 0.000 description 60
- 241000699670 Mus sp. Species 0.000 description 43
- 239000003925 fat Substances 0.000 description 31
- 238000010186 staining Methods 0.000 description 31
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 26
- 229940073450 sudan red Drugs 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 210000002376 aorta thoracic Anatomy 0.000 description 18
- 210000003462 vein Anatomy 0.000 description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 description 13
- 108010007622 LDL Lipoproteins Proteins 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 11
- 210000000709 aorta Anatomy 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 9
- 238000011813 knockout mouse model Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 210000003291 sinus of valsalva Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- -1 OCT compound Chemical class 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 101150092476 ABCA1 gene Proteins 0.000 description 3
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 210000004896 polypeptide structure Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710205202 Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
提供了一种多肽及其应用。该多肽包含由SEQ ID NO:1所示的氨基酸序列中16‑23个连续氨基酸所构成的肽段。该多肽可以改善代谢综合征、减肥、治疗非酒精性脂肪肝病和心血管疾病。
Description
PCT国内申请，说明书已公开。
Claims (8)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910807205.3A CN112442114A (zh) | 2019-08-29 | 2019-08-29 | 一种多肽及其应用 |
| CN2019108072053 | 2019-08-29 | ||
| PCT/CN2020/112007 WO2021037187A1 (zh) | 2019-08-29 | 2020-08-28 | 一种多肽及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113993883A true CN113993883A (zh) | 2022-01-28 |
Family
ID=74684626
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910807205.3A Pending CN112442114A (zh) | 2019-08-29 | 2019-08-29 | 一种多肽及其应用 |
| CN202080042030.2A Pending CN113993883A (zh) | 2019-08-29 | 2020-08-28 | 一种多肽及其应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910807205.3A Pending CN112442114A (zh) | 2019-08-29 | 2019-08-29 | 一种多肽及其应用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220298209A1 (zh) |
| EP (1) | EP4023663A4 (zh) |
| CN (2) | CN112442114A (zh) |
| WO (1) | WO2021037187A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001057188A2 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20080234192A1 (en) * | 2006-12-08 | 2008-09-25 | Washington, University Of | Compositions and methods of use for treating cardiovascular disease |
| CN101721712A (zh) * | 2008-10-21 | 2010-06-09 | 何明磊 | 一种双链聚乙二醇－胰岛素复合物及其制备方法 |
| US20120329703A1 (en) * | 2002-05-08 | 2012-12-27 | The Regents Of Te University Of California | Potent and Selective Mediators of Cholesterol Efflux |
| US20140336113A1 (en) * | 2011-10-06 | 2014-11-13 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| CN105008524A (zh) * | 2012-12-12 | 2015-10-28 | 东安大略研究所儿童医院有限公司 | 用于治疗脑癌的组合物和方法 |
| CN107011427A (zh) * | 2017-03-16 | 2017-08-04 | 深圳先进技术研究院 | 调节能量代谢的多肽及其用途 |
| CN109200273A (zh) * | 2017-07-04 | 2019-01-15 | 中国药科大学 | 一种多肽用于制备预防或治疗脂肪肝病药物的用途 |
| CN109420157A (zh) * | 2017-08-21 | 2019-03-05 | 华中科技大学 | 一种药物组合物的应用 |
| AU2018314773A1 (en) * | 2017-08-09 | 2020-03-26 | Sanofi | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
| CN111225680A (zh) * | 2017-10-18 | 2020-06-02 | 上海贺普药业股份有限公司 | 非酒精性脂肪性肝病的治疗药物 |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2375771A1 (fr) * | 1999-06-17 | 2000-12-28 | Aventis Pharma S.A. | Acides nucleiques et proteines correspondant au gene abc1 humain |
| WO2001032184A2 (en) * | 1999-11-01 | 2001-05-10 | Wisconsin Alumni Research Foundation | Abc1 modulation for the modulation of cholesterol transport |
| SG11201609084QA (en) * | 2014-05-02 | 2016-11-29 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| US10293043B2 (en) * | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
-
2019
- 2019-08-29 CN CN201910807205.3A patent/CN112442114A/zh active Pending
-
2020
- 2020-08-28 EP EP20855987.2A patent/EP4023663A4/en active Pending
- 2020-08-28 US US17/635,527 patent/US20220298209A1/en active Pending
- 2020-08-28 WO PCT/CN2020/112007 patent/WO2021037187A1/zh unknown
- 2020-08-28 CN CN202080042030.2A patent/CN113993883A/zh active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001057188A2 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20120329703A1 (en) * | 2002-05-08 | 2012-12-27 | The Regents Of Te University Of California | Potent and Selective Mediators of Cholesterol Efflux |
| US20080234192A1 (en) * | 2006-12-08 | 2008-09-25 | Washington, University Of | Compositions and methods of use for treating cardiovascular disease |
| CN101721712A (zh) * | 2008-10-21 | 2010-06-09 | 何明磊 | 一种双链聚乙二醇－胰岛素复合物及其制备方法 |
| US20140336113A1 (en) * | 2011-10-06 | 2014-11-13 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| CN105008524A (zh) * | 2012-12-12 | 2015-10-28 | 东安大略研究所儿童医院有限公司 | 用于治疗脑癌的组合物和方法 |
| CN107011427A (zh) * | 2017-03-16 | 2017-08-04 | 深圳先进技术研究院 | 调节能量代谢的多肽及其用途 |
| CN109200273A (zh) * | 2017-07-04 | 2019-01-15 | 中国药科大学 | 一种多肽用于制备预防或治疗脂肪肝病药物的用途 |
| AU2018314773A1 (en) * | 2017-08-09 | 2020-03-26 | Sanofi | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
| CN109420157A (zh) * | 2017-08-21 | 2019-03-05 | 华中科技大学 | 一种药物组合物的应用 |
| CN111225680A (zh) * | 2017-10-18 | 2020-06-02 | 上海贺普药业股份有限公司 | 非酒精性脂肪性肝病的治疗药物 |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
Non-Patent Citations (3)
| Title |
|---|
| M. PILAR VALDECANTOS等: "Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy", 《SCIENTIFIC REPORTS》, vol. 8, no. 16461, pages 1 - 15 * |
| 张颖玮，王艳侠，石岩等主编: "《肾脏病学现代基础与临床》", 内蒙古科学技术出版社, pages: 339 - 9 * |
| 梁辰: "16个氨基酸多肽对高脂饮食+CCl4诱导的非酒精性脂肪肝的保护性作用及机制研究", <中国优秀硕士学位论文全文数据库医药卫生科技辑>, pages 064 - 80 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4023663A1 (en) | 2022-07-06 |
| CN112442114A8 (zh) | 2021-04-16 |
| EP4023663A4 (en) | 2023-01-04 |
| US20220298209A1 (en) | 2022-09-22 |
| WO2021037187A1 (zh) | 2021-03-04 |
| CN112442114A (zh) | 2021-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pan et al. | A novel anti-inflammatory mechanism of high density lipoprotein through up-regulating annexin A1 in vascular endothelial cells | |
| US8916151B2 (en) | Method for treating a reduction of fertility | |
| JP2020007371A (ja) | 抗肥満及び抗糖尿作用を有するペプチド及びその用途 | |
| Ecelbarger et al. | Escape from vasopressin-induced antidiuresis: role of vasopressin resistance of the collecting duct | |
| US20110268768A1 (en) | Compositions and Methods for Treating Atherosclerosis | |
| CN105294859A (zh) | 脂蛋白复合物及其制备和用途 | |
| JPH11505807A (ja) | 生物学的活性が増加したキメラ脂肪体プロｇｒｆ類似体 | |
| US7700544B2 (en) | Compositions and methods for treating atherosclerosis | |
| Zhang et al. | Cordycepin (3′-deoxyadenosine) down-regulates the proinflammatory cytokines in inflammation-induced osteoporosis model | |
| JP2023083380A (ja) | インターロイキン－２２の治療用誘導体 | |
| CN113993883A (zh) | 一种多肽及其应用 | |
| Parolini et al. | Infusions of large synthetic HDL containing trimeric apoA-I stabilize atherosclerotic plaques in hypercholesterolemic rabbits | |
| US9539312B2 (en) | Nasal vaccine against the development of atherosclerosis disease and fatty liver | |
| US20150182602A1 (en) | Pharmaceutical formulations comprising paraoxonase | |
| US9610324B2 (en) | Apolipoprotein mixtures | |
| US8895502B2 (en) | β2-glycoprotein I peptide inhibitors | |
| EP2692862B1 (en) | Polyamide compound and pharmaceutical composition for treating mitochondrial genetic diseases | |
| WO1994027629A1 (en) | Method to control appetite and treat obesity | |
| Ni et al. | Enhanced delivery of human growth hormone across cell membrane by Tat-PTD | |
| JP3003978B2 (ja) | ペオニフロリン含有ｈｓｐ４７合成抑制剤 | |
| WO2023108126A1 (en) | Compositions and methods for oral administration | |
| JPH10330268A (ja) | ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤 | |
| JP2023521906A (ja) | 線維症の予防又は治療用組換え融合タンパク質 | |
| AU2014248252A1 (en) | Uses of cyclic peptides for treating and preventing atherosclerosis | |
| JPWO2006132245A1 (ja) | 腫瘍増殖抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |